Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 462

1.

White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.

Wiebenga OT, Schoonheim MM, Hulst HE, Nagtegaal GJ, Strijbis EM, Steenwijk MD, Polman CH, Pouwels PJ, Barkhof F, Geurts JJ.

AJNR Am J Neuroradiol. 2016 Jun;37(6):1030-7. doi: 10.3174/ajnr.A4690. Epub 2016 Mar 10.

2.

Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice.

Freedman MS, Comi G, De Stefano N, Barkhof F, Polman CH, Uitdehaag BM, Lehr L, Stubinski B, Kappos L.

Mult Scler Relat Disord. 2014 Mar;3(2):147-55. doi: 10.1016/j.msard.2013.07.001. Epub 2013 Jul 31. Review.

3.

Enhanced axonal metabolism during early natalizumab treatment in relapsing-remitting multiple sclerosis.

Wiebenga OT, Klauser AM, Schoonheim MM, Nagtegaal GJ, Steenwijk MD, van Rossum JA, Polman CH, Barkhof F, Pouwels PJ, Geurts JJ.

AJNR Am J Neuroradiol. 2015 Jun;36(6):1116-23. doi: 10.3174/ajnr.A4252. Epub 2015 Mar 5.

4.

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.

Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.

Mult Scler. 2015 Oct;21(12):1600-3. doi: 10.1177/1352458514567728. Epub 2015 Feb 6.

PMID:
25662344
5.

Functional brain networks: linking thalamic atrophy to clinical disability in multiple sclerosis, a multimodal fMRI and MEG study.

Tewarie P, Schoonheim MM, Schouten DI, Polman CH, Balk LJ, Uitdehaag BM, Geurts JJ, Hillebrand A, Barkhof F, Stam CJ.

Hum Brain Mapp. 2015 Feb;36(2):603-18. doi: 10.1002/hbm.22650. Epub 2014 Oct 8.

PMID:
25293505
6.

Molecular mechanism underlying the impact of vitamin D on disease activity of MS.

Munger KL, Köchert K, Simon KC, Kappos L, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Sandbrink R, Ascherio A, Pohl C.

Ann Clin Transl Neurol. 2014 Aug;1(8):605-17. doi: 10.1002/acn3.91. Epub 2014 Aug 22.

7.

Toward the use of proxy reports for estimating long-term patient-reported outcomes in multiple sclerosis.

Sonder JM, Balk LJ, van der Linden FA, Bosma LV, Polman CH, Uitdehaag BM.

Mult Scler. 2015 Dec;21(14):1865-71. doi: 10.1177/1352458514544078. Epub 2014 Sep 25.

PMID:
25257617
8.

Multiple sclerosis: current knowledge and future outlook.

Kamm CP, Uitdehaag BM, Polman CH.

Eur Neurol. 2014;72(3-4):132-41. doi: 10.1159/000360528. Epub 2014 Jul 30. Review.

9.

Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.

Vennegoor A, Rispens T, Van Oosten BW, Wattjes MP, Wondergem MJ, Teunissen CE, Van der Kleij D, Uitdehaag BM, Polman CH, Killestein J.

Mult Scler. 2015 Apr;21(4):481-4. doi: 10.1177/1352458514541507. Epub 2014 Jul 30.

PMID:
25078275
10.

Disruption of structural and functional networks in long-standing multiple sclerosis.

Tewarie P, Steenwijk MD, Tijms BM, Daams M, Balk LJ, Stam CJ, Uitdehaag BM, Polman CH, Geurts JJ, Barkhof F, Pouwels PJ, Vrenken H, Hillebrand A.

Hum Brain Mapp. 2014 Dec;35(12):5946-61. doi: 10.1002/hbm.22596. Epub 2014 Jul 22.

PMID:
25053254
11.

Detecting clinically-relevant changes in progressive multiple sclerosis.

Bosma LV, Sonder JM, Kragt JJ, Polman CH, Uitdehaag BM.

Mult Scler. 2015 Feb;21(2):171-9. doi: 10.1177/1352458514540969. Epub 2014 Jul 10.

PMID:
25013153
12.

Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.

Balk LJ, Steenwijk MD, Tewarie P, Daams M, Killestein J, Wattjes MP, Vrenken H, Barkhof F, Polman CH, Uitdehaag BM, Petzold A.

J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):419-24. doi: 10.1136/jnnp-2014-308189. Epub 2014 Jun 27.

PMID:
24973342
13.

A computer-based screening method for distress in patients with multiple sclerosis: a feasibility study.

Boeschoten RE, Uitdehaag BM, van Oppen P, de Groot V, Collette EH, Bakker KA, Polman CH, Dekker J.

JMIR Res Protoc. 2014 Jun 4;3(2):e29. doi: 10.2196/resprot.3098.

14.

Defining the clinical course of multiple sclerosis: the 2013 revisions.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH.

Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.

15.

Morphological features of MS lesions on FLAIR* at 7 T and their relation to patient characteristics.

Kilsdonk ID, Lopez-Soriano A, Kuijer JP, de Graaf WL, Castelijns JA, Polman CH, Luijten PR, Geurts JJ, Barkhof F, Wattjes MP.

J Neurol. 2014 Jul;261(7):1356-64. doi: 10.1007/s00415-014-7351-6. Epub 2014 Apr 29.

PMID:
24777693
16.

Structural degree predicts functional network connectivity: a multimodal resting-state fMRI and MEG study.

Tewarie P, Hillebrand A, van Dellen E, Schoonheim MM, Barkhof F, Polman CH, Beaulieu C, Gong G, van Dijk BW, Stam CJ.

Neuroimage. 2014 Aug 15;97:296-307. doi: 10.1016/j.neuroimage.2014.04.038. Epub 2014 Apr 23.

PMID:
24769185
17.

Do patient and proxy agree? Long-term changes in multiple sclerosis physical impact and walking ability on patient-reported outcome scales.

Sonder JM, Balk LJ, Bosma LV, Polman CH, Uitdehaag BM.

Mult Scler. 2014 Oct;20(12):1616-23. doi: 10.1177/1352458514529173. Epub 2014 Apr 7.

PMID:
24710798
18.

Client-centred therapy in multiple sclerosis: more intensive diagnostic evaluation and less intensive treatment.

Eyssen IC, Dekker J, de Groot V, Steultjens EM, Knol DL, Polman CH, Steultjens MP.

J Rehabil Med. 2014 Jun;46(6):527-31. doi: 10.2340/16501977-1797.

19.

A dam for retrograde axonal degeneration in multiple sclerosis?

Balk LJ, Twisk JW, Steenwijk MD, Daams M, Tewarie P, Killestein J, Uitdehaag BM, Polman CH, Petzold A.

J Neurol Neurosurg Psychiatry. 2014 Jul;85(7):782-9. doi: 10.1136/jnnp-2013-306902. Epub 2014 Jan 28.

PMID:
24474822
20.

Vitamin D as an early predictor of multiple sclerosis activity and progression.

Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, Kappos L, Pohl C.

JAMA Neurol. 2014 Mar;71(3):306-14. doi: 10.1001/jamaneurol.2013.5993.

Supplemental Content

Loading ...
Support Center